Summaries for Patients |

Diagnosis and Management of Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full reports titled “Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians” and “Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline.” They are in the 6 November 2007 issue of Annals of Internal Medicine (volume 147, pages 633-638 and 639-653). The authors of the first report are A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T.J. Wilt, S. Weinberger, and D.K. Owens, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians; the authors of the second report are T.J. Wilt, D. Niewoehner, R. MacDonald, and R.L. Kane.

Ann Intern Med. 2007;147(9):I-41. doi:10.7326/0003-4819-147-9-200711060-00002
Text Size: A A A

Who developed these guidelines?

The American College of Physicians (ACP) developed these recommendations. Members of the ACP are internists, which are specialists in the care of adults.

What is the problem and what is known about it so far?

Chronic obstructive pulmonary disease (COPD) is a disease of the airways and lungs that usually occurs in cigarette smokers. People with COPD get short of breath. Damage to the lungs and symptoms slowly worsen over time. Spirometry is a breathing test that can diagnose COPD on the basis of a measurement called FEV1 (forced expiratory volume in 1 second), which estimates the amount of air that a person exhales in 1 second compared with that of a typical healthy person of the same age and size. A person with a FEV1 of 60% exhales about 60% the amount that a typical healthy person the same age and size exhales in 1 second.

Doctors treat COPD with drugs that widen the airways of the lungs (beta-agonist or anticholinergic drugs) and drugs that decrease inflammation (corticosteroids). These drugs come in inhalers that allow patients to breathe in the drugs. Oxygen therapy can help some people with COPD. Pulmonary rehabilitation, which involves patient education and exercise, is another COPD treatment.

How did the ACP develop these recommendations?

The authors reviewed studies about the benefits and harms of various tests and treatments for COPD published between 1966 and March 2007.

What did the authors find?

The authors found little evidence that spirometry helps to select treatment. They did find that spirometry can be helpful in diagnosing COPD in patients who present with breathing symptoms, but it is not helpful in patients without symptoms.

The authors found strong evidence for a benefit of inhaled beta-agonists, anticholinergics, and corticosteroids in reducing symptoms, hospitalization, and death due to COPD. However, the studies of these drugs were mostly done in patients with an FEV1 less than 60% and might not apply to patients with less severe lung abnormality. Evidence for a benefit of oxygen therapy was found for patients with very low resting blood oxygen levels. Some weak evidence indicated that pulmonary rehabilitation may help patients with COPD symptoms and an FEV1 less than 50%.

What does the ACP suggest that patients and doctors do?

The ACP strongly recommends that doctors and patients:

1. Use spirometry to diagnose COPD in patients with shortness of breath, but not to look for COPD in patients without symptoms.

2. Treat COPD with 1 of the following drugs if spirometry shows that the FEV1 is less than 60% predicted: a long-acting beta-agonist, a long-acting anticholinergic, or a corticosteroid.

3. Consider oxygen therapy for patients with COPD who have very low blood oxygen levels at rest. The ACP weakly recommends that doctors and patients should:

1. Consider a combination of inhaled drugs if the FEV1 is less than 60% and symptoms continue during treatment with 1 drug.

2. Consider pulmonary rehabilitation for patients with COPD symptoms and an FEV1 less than 50% predicted.

What are the cautions related to these recommendations?

Recommendations may change as new studies become available.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.